What is Global Amyotrophic Lateral Sclerosis (ALS) Market?
The Global Amyotrophic Lateral Sclerosis (ALS) Market is a comprehensive study of the global market trends and growth prospects for ALS treatments. ALS, also known as Lou Gehrig's disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. The market for ALS treatments is a critical area of study as there is currently no cure for this devastating disease. The market encompasses various aspects, including the development of new treatments, the availability and cost of existing treatments, and the impact of these factors on patients and healthcare providers. The market is influenced by various factors, including the prevalence of ALS, advancements in medical technology, and the availability of funding for research and development. Despite the challenges posed by the disease, the ALS market continues to grow, driven by the urgent need for effective treatments and the ongoing efforts of researchers and healthcare providers worldwide. However, the market also faces several challenges, including the high cost of treatment and the lack of a definitive cure.
Riluzole, Edaravone (Radicava), Other in the Global Amyotrophic Lateral Sclerosis (ALS) Market:
Riluzole, Edaravone (Radicava), and other treatments form the basis of the Global Amyotrophic Lateral Sclerosis (ALS) Market. Riluzole is the first drug that was approved by the FDA for the treatment of ALS. It works by decreasing the release of glutamate, a chemical messenger in the brain, which is believed to damage nerve cells. Edaravone (Radicava) is a newer drug that was approved by the FDA in 2017. It is believed to work by relieving the effects of oxidative stress, which is thought to be a factor in the death of nerve cells in people with ALS. Other treatments in the market include physical therapy, occupational therapy, speech therapy, nutritional support, and respiratory therapy. These treatments aim to improve the quality of life for people with ALS by managing symptoms and slowing the progression of the disease. However, the effectiveness of these treatments varies from person to person, and they do not cure the disease.
Hospital, Drugs Store, Other in the Global Amyotrophic Lateral Sclerosis (ALS) Market:
The Global Amyotrophic Lateral Sclerosis (ALS) Market is utilized in various areas such as hospitals, drug stores, and others. Hospitals are the primary users of ALS treatments as they provide comprehensive care for patients, including diagnosis, treatment, and ongoing management of the disease. Drug stores also play a crucial role in the ALS market as they are the primary source of medications for patients. Other users of the ALS market include research institutions, home healthcare providers, and long-term care facilities. These institutions provide essential services for people with ALS, including research into new treatments, home-based care, and long-term support for patients who are unable to care for themselves. Despite the wide range of users, the ALS market faces several challenges, including the high cost of treatments and the lack of a definitive cure.
Global Amyotrophic Lateral Sclerosis (ALS) Market Outlook:
The Global Amyotrophic Lateral Sclerosis (ALS) Market outlook highlights that the market was valued at US$ 300 million in 2022. It is projected to reach a value of US$ 360.4 million by 2029, growing at a Compound Annual Growth Rate (CAGR) of 2.6% during the forecast period from 2023 to 2029. The product segment of Edaravone (Radicava) holds the largest share in the market, accounting for over 75% of the total market. This significant market share is attributed to the effectiveness of Edaravone in relieving the effects of oxidative stress, a factor believed to contribute to the death of nerve cells in people with ALS. Despite the challenges posed by the disease, the ALS market continues to grow, driven by the urgent need for effective treatments and the ongoing efforts of researchers and healthcare providers worldwide.
| Report Metric | Details |
| Report Name | Amyotrophic Lateral Sclerosis (ALS) Market |
| Accounted market size in 2022 | US$ 300 million |
| Forecasted market size in 2029 | US$ 379.1 million |
| CAGR | 2.6% |
| Base Year | 2022 |
| Forecasted years | 2023 - 2029 |
| Segment by Type |
|
| Segment by Application |
|
| Consumption by Region |
|
| By Company | Mitsubishi Tanabe Pharma, Sanofi, Mylan Pharma, Apotex, Glemark Generics, Covis Pharma, Sun Pharma, Lunan Pharma |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
